nodes	percent_of_prediction	percent_of_DWPC	metapath
Imatinib—CA9—cervical cancer	0.526	1	CbGaD
Imatinib—ABCG2—Topotecan—cervical cancer	0.125	0.634	CbGbCtD
Imatinib—ABCB1—Topotecan—cervical cancer	0.0449	0.229	CbGbCtD
Imatinib—CYP3A4—Topotecan—cervical cancer	0.0269	0.137	CbGbCtD
Imatinib—Pleuritic pain—Topotecan—cervical cancer	0.00612	0.0898	CcSEcCtD
Imatinib—Ponatinib—FGFR3—cervical cancer	0.00447	0.759	CrCbGaD
Imatinib—Bullous eruption—Topotecan—cervical cancer	0.00311	0.0456	CcSEcCtD
Imatinib—CA6—exocrine gland—cervical cancer	0.00264	0.0251	CbGeAlD
Imatinib—Myelosuppression—Topotecan—cervical cancer	0.00262	0.0384	CcSEcCtD
Imatinib—NTRK1—decidua—cervical cancer	0.00239	0.0228	CbGeAlD
Imatinib—Mucosal inflammation—Topotecan—cervical cancer	0.00222	0.0325	CcSEcCtD
Imatinib—Febrile neutropenia—Topotecan—cervical cancer	0.00204	0.03	CcSEcCtD
Imatinib—ABCA3—decidua—cervical cancer	0.00189	0.018	CbGeAlD
Imatinib—DDR1—uterine cervix—cervical cancer	0.00183	0.0174	CbGeAlD
Imatinib—Intestinal obstruction—Topotecan—cervical cancer	0.0018	0.0264	CcSEcCtD
Imatinib—ABCA3—endometrium—cervical cancer	0.00179	0.0171	CbGeAlD
Imatinib—Heartburn—Topotecan—cervical cancer	0.00179	0.0262	CcSEcCtD
Imatinib—DDR1—decidua—cervical cancer	0.00174	0.0166	CbGeAlD
Imatinib—Interstitial lung disease—Topotecan—cervical cancer	0.00174	0.0255	CcSEcCtD
Imatinib—ABCA3—mammalian vulva—cervical cancer	0.00173	0.0165	CbGeAlD
Imatinib—DDR1—endometrium—cervical cancer	0.00165	0.0158	CbGeAlD
Imatinib—Pleural effusion—Topotecan—cervical cancer	0.0016	0.0235	CcSEcCtD
Imatinib—DDR1—mammalian vulva—cervical cancer	0.0016	0.0152	CbGeAlD
Imatinib—KIT—exocrine gland—cervical cancer	0.00153	0.0146	CbGeAlD
Imatinib—DDR1—uterus—cervical cancer	0.00152	0.0145	CbGeAlD
Imatinib—Rigors—Topotecan—cervical cancer	0.0015	0.0221	CcSEcCtD
Imatinib—HIPK4—female reproductive system—cervical cancer	0.0015	0.0143	CbGeAlD
Imatinib—Nilotinib—CA9—cervical cancer	0.00142	0.241	CrCbGaD
Imatinib—Hyperbilirubinaemia—Topotecan—cervical cancer	0.00135	0.0198	CcSEcCtD
Imatinib—ABCA3—female gonad—cervical cancer	0.00135	0.0129	CbGeAlD
Imatinib—ABCA3—vagina—cervical cancer	0.00134	0.0128	CbGeAlD
Imatinib—Blood bilirubin increased—Topotecan—cervical cancer	0.0013	0.0191	CcSEcCtD
Imatinib—Bone pain—Topotecan—cervical cancer	0.00128	0.0188	CcSEcCtD
Imatinib—DDR1—female gonad—cervical cancer	0.00125	0.0119	CbGeAlD
Imatinib—DDR1—vagina—cervical cancer	0.00124	0.0118	CbGeAlD
Imatinib—Colitis—Topotecan—cervical cancer	0.00118	0.0173	CcSEcCtD
Imatinib—PIP4K2C—uterine cervix—cervical cancer	0.00113	0.0108	CbGeAlD
Imatinib—Neoplasm—Topotecan—cervical cancer	0.00111	0.0163	CcSEcCtD
Imatinib—CA7—renal system—cervical cancer	0.0011	0.0105	CbGeAlD
Imatinib—CA3—uterine cervix—cervical cancer	0.00108	0.0103	CbGeAlD
Imatinib—PIP4K2C—decidua—cervical cancer	0.00107	0.0102	CbGeAlD
Imatinib—Sepsis—Topotecan—cervical cancer	0.00107	0.0156	CcSEcCtD
Imatinib—PIP4K2C—endometrium—cervical cancer	0.00102	0.00973	CbGeAlD
Imatinib—LCK—uterine cervix—cervical cancer	0.001	0.00955	CbGeAlD
Imatinib—PIP4K2C—mammalian vulva—cervical cancer	0.000987	0.00941	CbGeAlD
Imatinib—LCK—decidua—cervical cancer	0.000954	0.0091	CbGeAlD
Imatinib—Dermatitis bullous—Topotecan—cervical cancer	0.000933	0.0137	CcSEcCtD
Imatinib—Lethargy—Topotecan—cervical cancer	0.00091	0.0133	CcSEcCtD
Imatinib—CA2—exocrine gland—cervical cancer	0.000908	0.00866	CbGeAlD
Imatinib—CA3—uterus—cervical cancer	0.000898	0.00856	CbGeAlD
Imatinib—LCK—mammalian vulva—cervical cancer	0.000876	0.00835	CbGeAlD
Imatinib—ABCA3—lymph node—cervical cancer	0.000868	0.00828	CbGeAlD
Imatinib—Cardiac arrest—Topotecan—cervical cancer	0.000848	0.0124	CcSEcCtD
Imatinib—PIP4K2C—female reproductive system—cervical cancer	0.000845	0.00806	CbGeAlD
Imatinib—LCK—uterus—cervical cancer	0.000835	0.00796	CbGeAlD
Imatinib—NQO2—uterine cervix—cervical cancer	0.000829	0.0079	CbGeAlD
Imatinib—ABL2—female gonad—cervical cancer	0.000813	0.00775	CbGeAlD
Imatinib—ABL2—vagina—cervical cancer	0.000808	0.0077	CbGeAlD
Imatinib—Aspartate aminotransferase increased—Topotecan—cervical cancer	0.000803	0.0118	CcSEcCtD
Imatinib—Cramp muscle—Topotecan—cervical cancer	0.000803	0.0118	CcSEcCtD
Imatinib—DDR1—lymph node—cervical cancer	0.000801	0.00764	CbGeAlD
Imatinib—NQO2—decidua—cervical cancer	0.00079	0.00753	CbGeAlD
Imatinib—PDGFRA—decidua—cervical cancer	0.000788	0.00751	CbGeAlD
Imatinib—Alanine aminotransferase increased—Topotecan—cervical cancer	0.000787	0.0115	CcSEcCtD
Imatinib—NQO2—renal system—cervical cancer	0.000775	0.00739	CbGeAlD
Imatinib—PDGFRA—renal system—cervical cancer	0.000773	0.00737	CbGeAlD
Imatinib—CA9—female reproductive system—cervical cancer	0.000773	0.00737	CbGeAlD
Imatinib—PIP4K2C—female gonad—cervical cancer	0.000769	0.00733	CbGeAlD
Imatinib—PIP4K2C—vagina—cervical cancer	0.000765	0.00729	CbGeAlD
Imatinib—NQO2—endometrium—cervical cancer	0.000749	0.00714	CbGeAlD
Imatinib—SLC22A2—renal system—cervical cancer	0.000734	0.007	CbGeAlD
Imatinib—Pancytopenia—Topotecan—cervical cancer	0.000732	0.0107	CcSEcCtD
Imatinib—CA3—vagina—cervical cancer	0.00073	0.00696	CbGeAlD
Imatinib—CSF1R—uterine cervix—cervical cancer	0.000728	0.00694	CbGeAlD
Imatinib—NQO2—mammalian vulva—cervical cancer	0.000725	0.00691	CbGeAlD
Imatinib—Neutropenia—Topotecan—cervical cancer	0.000721	0.0106	CcSEcCtD
Imatinib—CA12—renal system—cervical cancer	0.000714	0.0068	CbGeAlD
Imatinib—Weight increased—Topotecan—cervical cancer	0.000702	0.0103	CcSEcCtD
Imatinib—CSF1R—decidua—cervical cancer	0.000693	0.00661	CbGeAlD
Imatinib—Pneumonia—Topotecan—cervical cancer	0.000691	0.0101	CcSEcCtD
Imatinib—NQO2—uterus—cervical cancer	0.000691	0.00658	CbGeAlD
Imatinib—PDGFRA—uterus—cervical cancer	0.000689	0.00657	CbGeAlD
Imatinib—Infestation NOS—Topotecan—cervical cancer	0.000687	0.0101	CcSEcCtD
Imatinib—Infestation—Topotecan—cervical cancer	0.000687	0.0101	CcSEcCtD
Imatinib—LCK—female gonad—cervical cancer	0.000683	0.00651	CbGeAlD
Imatinib—LCK—vagina—cervical cancer	0.000679	0.00647	CbGeAlD
Imatinib—Neuropathy peripheral—Topotecan—cervical cancer	0.000674	0.00988	CcSEcCtD
Imatinib—Stomatitis—Topotecan—cervical cancer	0.00067	0.00983	CcSEcCtD
Imatinib—KIT—epithelium—cervical cancer	0.000666	0.00635	CbGeAlD
Imatinib—SLC47A1—uterine cervix—cervical cancer	0.000665	0.00634	CbGeAlD
Imatinib—KIT—uterine cervix—cervical cancer	0.000661	0.0063	CbGeAlD
Imatinib—Sweating—Topotecan—cervical cancer	0.000659	0.00966	CcSEcCtD
Imatinib—CSF1R—endometrium—cervical cancer	0.000658	0.00627	CbGeAlD
Imatinib—PDGFRB—epithelium—cervical cancer	0.000651	0.00621	CbGeAlD
Imatinib—Hepatobiliary disease—Topotecan—cervical cancer	0.00065	0.00953	CcSEcCtD
Imatinib—Epistaxis—Topotecan—cervical cancer	0.000648	0.00951	CcSEcCtD
Imatinib—PDGFRB—uterine cervix—cervical cancer	0.000645	0.00615	CbGeAlD
Imatinib—CSF1R—mammalian vulva—cervical cancer	0.000637	0.00607	CbGeAlD
Imatinib—SLC47A1—decidua—cervical cancer	0.000633	0.00604	CbGeAlD
Imatinib—KIT—decidua—cervical cancer	0.00063	0.006	CbGeAlD
Imatinib—SLC47A1—renal system—cervical cancer	0.000622	0.00593	CbGeAlD
Imatinib—NQO2—female reproductive system—cervical cancer	0.000621	0.00592	CbGeAlD
Imatinib—Haemoglobin—Topotecan—cervical cancer	0.00062	0.00909	CcSEcCtD
Imatinib—PDGFRA—female reproductive system—cervical cancer	0.000619	0.0059	CbGeAlD
Imatinib—Rhinitis—Topotecan—cervical cancer	0.000619	0.00907	CcSEcCtD
Imatinib—KIT—renal system—cervical cancer	0.000618	0.00589	CbGeAlD
Imatinib—Haemorrhage—Topotecan—cervical cancer	0.000617	0.00905	CcSEcCtD
Imatinib—PDGFRB—decidua—cervical cancer	0.000615	0.00586	CbGeAlD
Imatinib—Hypoaesthesia—Topotecan—cervical cancer	0.000614	0.009	CcSEcCtD
Imatinib—Pharyngitis—Topotecan—cervical cancer	0.000612	0.00898	CcSEcCtD
Imatinib—CSF1R—uterus—cervical cancer	0.000607	0.00578	CbGeAlD
Imatinib—PDGFRB—renal system—cervical cancer	0.000604	0.00576	CbGeAlD
Imatinib—SLC47A1—endometrium—cervical cancer	0.000601	0.00573	CbGeAlD
Imatinib—KIT—endometrium—cervical cancer	0.000598	0.0057	CbGeAlD
Imatinib—PDGFRB—endometrium—cervical cancer	0.000584	0.00556	CbGeAlD
Imatinib—SLC47A1—mammalian vulva—cervical cancer	0.000581	0.00554	CbGeAlD
Imatinib—KIT—mammalian vulva—cervical cancer	0.000578	0.00551	CbGeAlD
Imatinib—ABL1—uterine cervix—cervical cancer	0.000575	0.00548	CbGeAlD
Imatinib—CA12—female reproductive system—cervical cancer	0.000572	0.00545	CbGeAlD
Imatinib—CA1—renal system—cervical cancer	0.000565	0.00539	CbGeAlD
Imatinib—NQO2—female gonad—cervical cancer	0.000565	0.00539	CbGeAlD
Imatinib—PDGFRB—mammalian vulva—cervical cancer	0.000565	0.00538	CbGeAlD
Imatinib—PDGFRA—female gonad—cervical cancer	0.000564	0.00537	CbGeAlD
Imatinib—NQO2—vagina—cervical cancer	0.000562	0.00535	CbGeAlD
Imatinib—PDGFRA—vagina—cervical cancer	0.00056	0.00534	CbGeAlD
Imatinib—Angiopathy—Topotecan—cervical cancer	0.00056	0.00821	CcSEcCtD
Imatinib—Immune system disorder—Topotecan—cervical cancer	0.000557	0.00817	CcSEcCtD
Imatinib—Mediastinal disorder—Topotecan—cervical cancer	0.000556	0.00816	CcSEcCtD
Imatinib—SLC47A1—uterus—cervical cancer	0.000554	0.00528	CbGeAlD
Imatinib—Chills—Topotecan—cervical cancer	0.000554	0.00812	CcSEcCtD
Imatinib—KIT—uterus—cervical cancer	0.000551	0.00525	CbGeAlD
Imatinib—ABL1—decidua—cervical cancer	0.000548	0.00522	CbGeAlD
Imatinib—ORM1—endometrium—cervical cancer	0.000548	0.00522	CbGeAlD
Imatinib—Alopecia—Topotecan—cervical cancer	0.000545	0.008	CcSEcCtD
Imatinib—CSF1R—female reproductive system—cervical cancer	0.000545	0.0052	CbGeAlD
Imatinib—ABL1—renal system—cervical cancer	0.000538	0.00513	CbGeAlD
Imatinib—PDGFRB—uterus—cervical cancer	0.000538	0.00513	CbGeAlD
Imatinib—Malnutrition—Topotecan—cervical cancer	0.000537	0.00788	CcSEcCtD
Imatinib—ABL2—lymph node—cervical cancer	0.000523	0.00498	CbGeAlD
Imatinib—ABL1—endometrium—cervical cancer	0.00052	0.00496	CbGeAlD
Imatinib—Back pain—Topotecan—cervical cancer	0.00052	0.00762	CcSEcCtD
Imatinib—SLC22A1—renal system—cervical cancer	0.000519	0.00495	CbGeAlD
Imatinib—Muscle spasms—Topotecan—cervical cancer	0.000516	0.00757	CcSEcCtD
Imatinib—ABL1—mammalian vulva—cervical cancer	0.000503	0.0048	CbGeAlD
Imatinib—Ill-defined disorder—Topotecan—cervical cancer	0.000498	0.00731	CcSEcCtD
Imatinib—SLC47A1—female reproductive system—cervical cancer	0.000498	0.00475	CbGeAlD
Imatinib—Anaemia—Topotecan—cervical cancer	0.000496	0.00728	CcSEcCtD
Imatinib—CSF1R—female gonad—cervical cancer	0.000496	0.00473	CbGeAlD
Imatinib—KIT—female reproductive system—cervical cancer	0.000495	0.00472	CbGeAlD
Imatinib—PIP4K2C—lymph node—cervical cancer	0.000495	0.00471	CbGeAlD
Imatinib—CSF1R—vagina—cervical cancer	0.000493	0.0047	CbGeAlD
Imatinib—Angioedema—Topotecan—cervical cancer	0.000491	0.0072	CcSEcCtD
Imatinib—Malaise—Topotecan—cervical cancer	0.000484	0.0071	CcSEcCtD
Imatinib—PDGFRB—female reproductive system—cervical cancer	0.000484	0.00461	CbGeAlD
Imatinib—Leukopenia—Topotecan—cervical cancer	0.000481	0.00705	CcSEcCtD
Imatinib—ABL1—uterus—cervical cancer	0.000479	0.00457	CbGeAlD
Imatinib—CA3—lymph node—cervical cancer	0.000472	0.0045	CbGeAlD
Imatinib—Cough—Topotecan—cervical cancer	0.000469	0.00687	CcSEcCtD
Imatinib—Myalgia—Topotecan—cervical cancer	0.000457	0.00671	CcSEcCtD
Imatinib—Chest pain—Topotecan—cervical cancer	0.000457	0.00671	CcSEcCtD
Imatinib—Arthralgia—Topotecan—cervical cancer	0.000457	0.00671	CcSEcCtD
Imatinib—Unspecified disorder of skin and subcutaneous tissue—Topotecan—cervical cancer	0.000454	0.00666	CcSEcCtD
Imatinib—ORM1—female reproductive system—cervical cancer	0.000454	0.00432	CbGeAlD
Imatinib—SLC47A1—female gonad—cervical cancer	0.000453	0.00432	CbGeAlD
Imatinib—CA1—female reproductive system—cervical cancer	0.000453	0.00432	CbGeAlD
Imatinib—Discomfort—Topotecan—cervical cancer	0.000452	0.00663	CcSEcCtD
Imatinib—KIT—female gonad—cervical cancer	0.000451	0.00429	CbGeAlD
Imatinib—SLC47A1—vagina—cervical cancer	0.00045	0.00429	CbGeAlD
Imatinib—KIT—vagina—cervical cancer	0.000448	0.00427	CbGeAlD
Imatinib—PDGFRB—female gonad—cervical cancer	0.00044	0.00419	CbGeAlD
Imatinib—LCK—lymph node—cervical cancer	0.000439	0.00418	CbGeAlD
Imatinib—Anaphylactic shock—Topotecan—cervical cancer	0.000438	0.00643	CcSEcCtD
Imatinib—PDGFRB—vagina—cervical cancer	0.000437	0.00417	CbGeAlD
Imatinib—Infection—Topotecan—cervical cancer	0.000436	0.00639	CcSEcCtD
Imatinib—ABL1—female reproductive system—cervical cancer	0.000431	0.00411	CbGeAlD
Imatinib—Nervous system disorder—Topotecan—cervical cancer	0.00043	0.0063	CcSEcCtD
Imatinib—Thrombocytopenia—Topotecan—cervical cancer	0.000429	0.00629	CcSEcCtD
Imatinib—Skin disorder—Topotecan—cervical cancer	0.000426	0.00624	CcSEcCtD
Imatinib—Hyperhidrosis—Topotecan—cervical cancer	0.000424	0.00621	CcSEcCtD
Imatinib—Anorexia—Topotecan—cervical cancer	0.000418	0.00613	CcSEcCtD
Imatinib—Musculoskeletal discomfort—Topotecan—cervical cancer	0.000399	0.00586	CcSEcCtD
Imatinib—CA2—epithelium—cervical cancer	0.000395	0.00377	CbGeAlD
Imatinib—Paraesthesia—Topotecan—cervical cancer	0.000394	0.00577	CcSEcCtD
Imatinib—ABL1—female gonad—cervical cancer	0.000392	0.00374	CbGeAlD
Imatinib—Dyspnoea—Topotecan—cervical cancer	0.000391	0.00573	CcSEcCtD
Imatinib—ABL1—vagina—cervical cancer	0.00039	0.00372	CbGeAlD
Imatinib—Dyspepsia—Topotecan—cervical cancer	0.000386	0.00566	CcSEcCtD
Imatinib—Decreased appetite—Topotecan—cervical cancer	0.000381	0.00559	CcSEcCtD
Imatinib—Gastrointestinal disorder—Topotecan—cervical cancer	0.000378	0.00555	CcSEcCtD
Imatinib—Fatigue—Topotecan—cervical cancer	0.000378	0.00554	CcSEcCtD
Imatinib—SLC22A1—vagina—cervical cancer	0.000376	0.00358	CbGeAlD
Imatinib—Constipation—Topotecan—cervical cancer	0.000375	0.0055	CcSEcCtD
Imatinib—Pain—Topotecan—cervical cancer	0.000375	0.0055	CcSEcCtD
Imatinib—CA2—decidua—cervical cancer	0.000373	0.00356	CbGeAlD
Imatinib—CA2—renal system—cervical cancer	0.000366	0.00349	CbGeAlD
Imatinib—NQO2—lymph node—cervical cancer	0.000363	0.00346	CbGeAlD
Imatinib—ABCG2—uterine cervix—cervical cancer	0.000363	0.00346	CbGeAlD
Imatinib—PDGFRA—lymph node—cervical cancer	0.000362	0.00345	CbGeAlD
Imatinib—Feeling abnormal—Topotecan—cervical cancer	0.000361	0.0053	CcSEcCtD
Imatinib—Gastrointestinal pain—Topotecan—cervical cancer	0.000358	0.00526	CcSEcCtD
Imatinib—Urticaria—Topotecan—cervical cancer	0.000348	0.00511	CcSEcCtD
Imatinib—Body temperature increased—Topotecan—cervical cancer	0.000347	0.00508	CcSEcCtD
Imatinib—Abdominal pain—Topotecan—cervical cancer	0.000347	0.00508	CcSEcCtD
Imatinib—ABCG2—decidua—cervical cancer	0.000346	0.00329	CbGeAlD
Imatinib—CA2—mammalian vulva—cervical cancer	0.000343	0.00327	CbGeAlD
Imatinib—CYP3A5—uterine cervix—cervical cancer	0.000337	0.00321	CbGeAlD
Imatinib—ABCG2—endometrium—cervical cancer	0.000328	0.00313	CbGeAlD
Imatinib—CYP1A2—renal system—cervical cancer	0.000327	0.00311	CbGeAlD
Imatinib—Hypersensitivity—Topotecan—cervical cancer	0.000323	0.00474	CcSEcCtD
Imatinib—CSF1R—lymph node—cervical cancer	0.000319	0.00304	CbGeAlD
Imatinib—ABCG2—mammalian vulva—cervical cancer	0.000317	0.00303	CbGeAlD
Imatinib—CYP3A5—renal system—cervical cancer	0.000315	0.003	CbGeAlD
Imatinib—Asthenia—Topotecan—cervical cancer	0.000315	0.00461	CcSEcCtD
Imatinib—Pruritus—Topotecan—cervical cancer	0.00031	0.00455	CcSEcCtD
Imatinib—PTGS1—epithelium—cervical cancer	0.000305	0.00291	CbGeAlD
Imatinib—PTGS1—uterine cervix—cervical cancer	0.000303	0.00288	CbGeAlD
Imatinib—ABCG2—uterus—cervical cancer	0.000302	0.00288	CbGeAlD
Imatinib—Diarrhoea—Topotecan—cervical cancer	0.0003	0.0044	CcSEcCtD
Imatinib—CA2—female reproductive system—cervical cancer	0.000293	0.0028	CbGeAlD
Imatinib—SLC47A1—lymph node—cervical cancer	0.000291	0.00278	CbGeAlD
Imatinib—Dizziness—Topotecan—cervical cancer	0.00029	0.00425	CcSEcCtD
Imatinib—CYP2C19—vagina—cervical cancer	0.00029	0.00276	CbGeAlD
Imatinib—KIT—lymph node—cervical cancer	0.00029	0.00276	CbGeAlD
Imatinib—PTGS1—renal system—cervical cancer	0.000283	0.0027	CbGeAlD
Imatinib—PDGFRB—lymph node—cervical cancer	0.000283	0.0027	CbGeAlD
Imatinib—Vomiting—Topotecan—cervical cancer	0.000279	0.00409	CcSEcCtD
Imatinib—Rash—Topotecan—cervical cancer	0.000276	0.00405	CcSEcCtD
Imatinib—Dermatitis—Topotecan—cervical cancer	0.000276	0.00405	CcSEcCtD
Imatinib—Headache—Topotecan—cervical cancer	0.000275	0.00403	CcSEcCtD
Imatinib—PTGS1—endometrium—cervical cancer	0.000274	0.00261	CbGeAlD
Imatinib—CA2—female gonad—cervical cancer	0.000267	0.00255	CbGeAlD
Imatinib—CA2—vagina—cervical cancer	0.000265	0.00253	CbGeAlD
Imatinib—ORM1—lymph node—cervical cancer	0.000265	0.00253	CbGeAlD
Imatinib—CA1—lymph node—cervical cancer	0.000265	0.00253	CbGeAlD
Imatinib—PTGS1—mammalian vulva—cervical cancer	0.000265	0.00252	CbGeAlD
Imatinib—Nausea—Topotecan—cervical cancer	0.00026	0.00382	CcSEcCtD
Imatinib—PTGS1—uterus—cervical cancer	0.000252	0.0024	CbGeAlD
Imatinib—ABL1—lymph node—cervical cancer	0.000252	0.0024	CbGeAlD
Imatinib—CYP2C9—female reproductive system—cervical cancer	0.000248	0.00237	CbGeAlD
Imatinib—ABCG2—female gonad—cervical cancer	0.000247	0.00236	CbGeAlD
Imatinib—ABCG2—vagina—cervical cancer	0.000246	0.00234	CbGeAlD
Imatinib—CYP3A4—renal system—cervical cancer	0.000236	0.00225	CbGeAlD
Imatinib—ALB—lymph node—cervical cancer	0.000233	0.00222	CbGeAlD
Imatinib—CYP2D6—renal system—cervical cancer	0.000233	0.00222	CbGeAlD
Imatinib—CYP3A5—female gonad—cervical cancer	0.00023	0.00219	CbGeAlD
Imatinib—CYP3A5—vagina—cervical cancer	0.000228	0.00218	CbGeAlD
Imatinib—PTGS1—female reproductive system—cervical cancer	0.000227	0.00216	CbGeAlD
Imatinib—PTGS1—female gonad—cervical cancer	0.000206	0.00197	CbGeAlD
Imatinib—PTGS1—vagina—cervical cancer	0.000205	0.00195	CbGeAlD
Imatinib—CYP3A4—female reproductive system—cervical cancer	0.000189	0.0018	CbGeAlD
Imatinib—CYP2D6—female reproductive system—cervical cancer	0.000186	0.00178	CbGeAlD
Imatinib—ABCB1—epithelium—cervical cancer	0.00018	0.00172	CbGeAlD
Imatinib—ABCB1—uterine cervix—cervical cancer	0.000179	0.00171	CbGeAlD
Imatinib—CA2—lymph node—cervical cancer	0.000172	0.00164	CbGeAlD
Imatinib—ABCB1—decidua—cervical cancer	0.00017	0.00162	CbGeAlD
Imatinib—CYP2D6—female gonad—cervical cancer	0.00017	0.00162	CbGeAlD
Imatinib—ABCB1—renal system—cervical cancer	0.000167	0.0016	CbGeAlD
Imatinib—ABCB1—endometrium—cervical cancer	0.000162	0.00154	CbGeAlD
Imatinib—ABCG2—lymph node—cervical cancer	0.000159	0.00152	CbGeAlD
Imatinib—ABCB1—mammalian vulva—cervical cancer	0.000157	0.00149	CbGeAlD
Imatinib—ABCB1—uterus—cervical cancer	0.000149	0.00142	CbGeAlD
Imatinib—ABCB1—female reproductive system—cervical cancer	0.000134	0.00128	CbGeAlD
Imatinib—PTGS1—lymph node—cervical cancer	0.000133	0.00126	CbGeAlD
Imatinib—ABCB1—female gonad—cervical cancer	0.000122	0.00116	CbGeAlD
Imatinib—ABCB1—vagina—cervical cancer	0.000121	0.00116	CbGeAlD
Imatinib—ABCB1—lymph node—cervical cancer	7.84e-05	0.000747	CbGeAlD
Imatinib—LCK—Adaptive Immune System—HLA-DQB1—cervical cancer	2.66e-05	0.000269	CbGpPWpGaD
Imatinib—KIT—Innate Immune System—CASP8—cervical cancer	2.64e-05	0.000267	CbGpPWpGaD
Imatinib—LCK—Signaling by EGFR in Cancer—EGFR—cervical cancer	2.64e-05	0.000267	CbGpPWpGaD
Imatinib—PDGFRB—Innate Immune System—FGFR3—cervical cancer	2.63e-05	0.000266	CbGpPWpGaD
Imatinib—LCK—Signaling by PDGF—EGFR—cervical cancer	2.63e-05	0.000266	CbGpPWpGaD
Imatinib—LCK—NGF signalling via TRKA from the plasma membrane—STAT3—cervical cancer	2.62e-05	0.000265	CbGpPWpGaD
Imatinib—LCK—Signaling by NGF—MTOR—cervical cancer	2.61e-05	0.000263	CbGpPWpGaD
Imatinib—ABL1—Integrated Pancreatic Cancer Pathway—TP53—cervical cancer	2.58e-05	0.000261	CbGpPWpGaD
Imatinib—PDGFRB—Immune System—HLA-DPB1—cervical cancer	2.57e-05	0.00026	CbGpPWpGaD
Imatinib—ABL1—Innate Immune System—FGFR3—cervical cancer	2.57e-05	0.000259	CbGpPWpGaD
Imatinib—PDGFRA—Signaling by NGF—EGFR—cervical cancer	2.53e-05	0.000256	CbGpPWpGaD
Imatinib—PDGFRB—Adaptive Immune System—FGFR3—cervical cancer	2.53e-05	0.000256	CbGpPWpGaD
Imatinib—KIT—Signaling Pathways—WNT5A—cervical cancer	2.51e-05	0.000254	CbGpPWpGaD
Imatinib—PDGFRB—Signaling by NGF—STAT3—cervical cancer	2.51e-05	0.000254	CbGpPWpGaD
Imatinib—ABL1—Immune System—HLA-DPB1—cervical cancer	2.51e-05	0.000253	CbGpPWpGaD
Imatinib—PDGFRA—Innate Immune System—CASP8—cervical cancer	2.5e-05	0.000253	CbGpPWpGaD
Imatinib—LCK—B Cell Activation—EGFR—cervical cancer	2.49e-05	0.000251	CbGpPWpGaD
Imatinib—ABCG2—Metabolism—CA9—cervical cancer	2.48e-05	0.000251	CbGpPWpGaD
Imatinib—PDGFRB—Signaling Pathways—AKAP13—cervical cancer	2.48e-05	0.000251	CbGpPWpGaD
Imatinib—LCK—Adaptive Immune System—CD8A—cervical cancer	2.48e-05	0.000251	CbGpPWpGaD
Imatinib—CYP3A7—Metabolism—CA9—cervical cancer	2.46e-05	0.000249	CbGpPWpGaD
Imatinib—SLC22A2—Metabolism—CA9—cervical cancer	2.46e-05	0.000248	CbGpPWpGaD
Imatinib—LCK—Disease—WNT5A—cervical cancer	2.46e-05	0.000248	CbGpPWpGaD
Imatinib—NTRK1—Signaling Pathways—NOTCH2—cervical cancer	2.41e-05	0.000243	CbGpPWpGaD
Imatinib—LCK—Signaling by NGF—CASP3—cervical cancer	2.4e-05	0.000242	CbGpPWpGaD
Imatinib—PTGS1—Metabolism—CA9—cervical cancer	2.38e-05	0.000241	CbGpPWpGaD
Imatinib—LCK—NGF signalling via TRKA from the plasma membrane—EGFR—cervical cancer	2.38e-05	0.000241	CbGpPWpGaD
Imatinib—PDGFRA—Signaling Pathways—WNT5A—cervical cancer	2.38e-05	0.00024	CbGpPWpGaD
Imatinib—CA2—Metabolism—MTHFR—cervical cancer	2.36e-05	0.000239	CbGpPWpGaD
Imatinib—KIT—Immune System—HLA-DQB1—cervical cancer	2.35e-05	0.000238	CbGpPWpGaD
Imatinib—ABCB1—Integrated Pancreatic Cancer Pathway—CASP8—cervical cancer	2.29e-05	0.000232	CbGpPWpGaD
Imatinib—SLC22A1—Metabolism—CA9—cervical cancer	2.29e-05	0.000231	CbGpPWpGaD
Imatinib—PDGFRB—Signaling by NGF—EGFR—cervical cancer	2.28e-05	0.000231	CbGpPWpGaD
Imatinib—LCK—Signaling Pathways—WNT2—cervical cancer	2.27e-05	0.000229	CbGpPWpGaD
Imatinib—CA1—Metabolism—MTHFR—cervical cancer	2.27e-05	0.000229	CbGpPWpGaD
Imatinib—PDGFRB—Innate Immune System—CASP8—cervical cancer	2.25e-05	0.000228	CbGpPWpGaD
Imatinib—PDGFRA—Immune System—HLA-DQB1—cervical cancer	2.23e-05	0.000225	CbGpPWpGaD
Imatinib—KIT—Immune System—CD8A—cervical cancer	2.2e-05	0.000222	CbGpPWpGaD
Imatinib—ABL1—Innate Immune System—CASP8—cervical cancer	2.19e-05	0.000222	CbGpPWpGaD
Imatinib—KIT—Innate Immune System—MTOR—cervical cancer	2.17e-05	0.00022	CbGpPWpGaD
Imatinib—KIT—Innate Immune System—CD4—cervical cancer	2.17e-05	0.000219	CbGpPWpGaD
Imatinib—PDGFRB—Signaling Pathways—WNT5A—cervical cancer	2.14e-05	0.000217	CbGpPWpGaD
Imatinib—LCK—Innate Immune System—FGFR3—cervical cancer	2.11e-05	0.000214	CbGpPWpGaD
Imatinib—KIT—Adaptive Immune System—MTOR—cervical cancer	2.09e-05	0.000211	CbGpPWpGaD
Imatinib—KIT—Adaptive Immune System—CD4—cervical cancer	2.08e-05	0.00021	CbGpPWpGaD
Imatinib—PDGFRA—Immune System—CD8A—cervical cancer	2.08e-05	0.00021	CbGpPWpGaD
Imatinib—KIT—Disease—HES1—cervical cancer	2.06e-05	0.000209	CbGpPWpGaD
Imatinib—LCK—Immune System—HLA-DPB1—cervical cancer	2.06e-05	0.000209	CbGpPWpGaD
Imatinib—PDGFRA—Innate Immune System—MTOR—cervical cancer	2.06e-05	0.000208	CbGpPWpGaD
Imatinib—PDGFRA—Innate Immune System—CD4—cervical cancer	2.05e-05	0.000207	CbGpPWpGaD
Imatinib—LCK—Cytokine Signaling in Immune system—STAT3—cervical cancer	2.05e-05	0.000207	CbGpPWpGaD
Imatinib—LCK—Adaptive Immune System—FGFR3—cervical cancer	2.03e-05	0.000205	CbGpPWpGaD
Imatinib—LCK—Signaling by NGF—STAT3—cervical cancer	2.01e-05	0.000204	CbGpPWpGaD
Imatinib—ABL1—Axon guidance—EGFR—cervical cancer	2.01e-05	0.000203	CbGpPWpGaD
Imatinib—PDGFRB—Immune System—HLA-DQB1—cervical cancer	2.01e-05	0.000203	CbGpPWpGaD
Imatinib—CA9—Metabolism—MTHFR—cervical cancer	1.99e-05	0.000201	CbGpPWpGaD
Imatinib—LCK—Signaling Pathways—AKAP13—cervical cancer	1.99e-05	0.000201	CbGpPWpGaD
Imatinib—PDGFRA—Adaptive Immune System—MTOR—cervical cancer	1.97e-05	0.0002	CbGpPWpGaD
Imatinib—NTRK1—Signaling Pathways—HES1—cervical cancer	1.97e-05	0.000199	CbGpPWpGaD
Imatinib—PDGFRA—Adaptive Immune System—CD4—cervical cancer	1.97e-05	0.000199	CbGpPWpGaD
Imatinib—ABL1—Immune System—HLA-DQB1—cervical cancer	1.96e-05	0.000198	CbGpPWpGaD
Imatinib—PDGFRA—Disease—HES1—cervical cancer	1.95e-05	0.000198	CbGpPWpGaD
Imatinib—KIT—Innate Immune System—CTNNB1—cervical cancer	1.93e-05	0.000195	CbGpPWpGaD
Imatinib—PDGFRB—Immune System—CD8A—cervical cancer	1.87e-05	0.00019	CbGpPWpGaD
Imatinib—PDGFRB—Innate Immune System—MTOR—cervical cancer	1.85e-05	0.000187	CbGpPWpGaD
Imatinib—PDGFRB—Innate Immune System—CD4—cervical cancer	1.85e-05	0.000187	CbGpPWpGaD
Imatinib—LCK—Signaling by NGF—EGFR—cervical cancer	1.83e-05	0.000185	CbGpPWpGaD
Imatinib—ABL1—Immune System—CD8A—cervical cancer	1.83e-05	0.000185	CbGpPWpGaD
Imatinib—PDGFRA—Innate Immune System—CTNNB1—cervical cancer	1.82e-05	0.000184	CbGpPWpGaD
Imatinib—KIT—Disease—MTHFR—cervical cancer	1.81e-05	0.000183	CbGpPWpGaD
Imatinib—ABL1—Developmental Biology—CTNNB1—cervical cancer	1.81e-05	0.000183	CbGpPWpGaD
Imatinib—KIT—Disease—TERT—cervical cancer	1.81e-05	0.000183	CbGpPWpGaD
Imatinib—LCK—Innate Immune System—CASP8—cervical cancer	1.81e-05	0.000183	CbGpPWpGaD
Imatinib—ABL1—Innate Immune System—MTOR—cervical cancer	1.8e-05	0.000182	CbGpPWpGaD
Imatinib—ABL1—Innate Immune System—CD4—cervical cancer	1.8e-05	0.000182	CbGpPWpGaD
Imatinib—KIT—Immune System—FGFR3—cervical cancer	1.8e-05	0.000182	CbGpPWpGaD
Imatinib—PDGFRB—Adaptive Immune System—MTOR—cervical cancer	1.78e-05	0.00018	CbGpPWpGaD
Imatinib—CYP3A5—Metabolism—CA9—cervical cancer	1.78e-05	0.00018	CbGpPWpGaD
Imatinib—PDGFRB—Adaptive Immune System—CD4—cervical cancer	1.78e-05	0.000179	CbGpPWpGaD
Imatinib—KIT—Signaling Pathways—NOTCH2—cervical cancer	1.76e-05	0.000178	CbGpPWpGaD
Imatinib—PDGFRB—Disease—HES1—cervical cancer	1.76e-05	0.000178	CbGpPWpGaD
Imatinib—ABCB1—Integrated Pancreatic Cancer Pathway—CASP3—cervical cancer	1.73e-05	0.000175	CbGpPWpGaD
Imatinib—NTRK1—Signaling Pathways—TERT—cervical cancer	1.73e-05	0.000175	CbGpPWpGaD
Imatinib—LCK—Signaling Pathways—WNT5A—cervical cancer	1.72e-05	0.000174	CbGpPWpGaD
Imatinib—PDGFRA—Disease—MTHFR—cervical cancer	1.72e-05	0.000174	CbGpPWpGaD
Imatinib—PDGFRA—Disease—TERT—cervical cancer	1.71e-05	0.000173	CbGpPWpGaD
Imatinib—PDGFRA—Immune System—FGFR3—cervical cancer	1.7e-05	0.000172	CbGpPWpGaD
Imatinib—ABCB1—Integrated Pancreatic Cancer Pathway—CTNNB1—cervical cancer	1.67e-05	0.000169	CbGpPWpGaD
Imatinib—PDGFRA—Signaling Pathways—NOTCH2—cervical cancer	1.67e-05	0.000169	CbGpPWpGaD
Imatinib—KIT—Disease—FGFR3—cervical cancer	1.66e-05	0.000168	CbGpPWpGaD
Imatinib—PDGFRB—Innate Immune System—CTNNB1—cervical cancer	1.64e-05	0.000166	CbGpPWpGaD
Imatinib—LCK—Immune System—HLA-DQB1—cervical cancer	1.61e-05	0.000163	CbGpPWpGaD
Imatinib—ABL1—Innate Immune System—CTNNB1—cervical cancer	1.6e-05	0.000162	CbGpPWpGaD
Imatinib—NTRK1—Signaling Pathways—FGFR3—cervical cancer	1.59e-05	0.00016	CbGpPWpGaD
Imatinib—ABL1—Developmental Biology—STAT3—cervical cancer	1.58e-05	0.00016	CbGpPWpGaD
Imatinib—PDGFRA—Disease—FGFR3—cervical cancer	1.57e-05	0.000159	CbGpPWpGaD
Imatinib—KIT—Disease—NOTCH1—cervical cancer	1.56e-05	0.000158	CbGpPWpGaD
Imatinib—PDGFRB—Disease—MTHFR—cervical cancer	1.55e-05	0.000156	CbGpPWpGaD
Imatinib—PDGFRB—Disease—TERT—cervical cancer	1.54e-05	0.000156	CbGpPWpGaD
Imatinib—KIT—Immune System—CASP8—cervical cancer	1.54e-05	0.000155	CbGpPWpGaD
Imatinib—PDGFRB—Immune System—FGFR3—cervical cancer	1.53e-05	0.000155	CbGpPWpGaD
Imatinib—ALB—Metabolism—CA9—cervical cancer	1.53e-05	0.000155	CbGpPWpGaD
Imatinib—KIT—Innate Immune System—EGFR—cervical cancer	1.53e-05	0.000154	CbGpPWpGaD
Imatinib—LCK—Immune System—CD8A—cervical cancer	1.5e-05	0.000152	CbGpPWpGaD
Imatinib—PDGFRB—Signaling Pathways—NOTCH2—cervical cancer	1.5e-05	0.000152	CbGpPWpGaD
Imatinib—ABL1—Immune System—FGFR3—cervical cancer	1.49e-05	0.000151	CbGpPWpGaD
Imatinib—NTRK1—Signaling Pathways—NOTCH1—cervical cancer	1.49e-05	0.000151	CbGpPWpGaD
Imatinib—LCK—Innate Immune System—MTOR—cervical cancer	1.49e-05	0.00015	CbGpPWpGaD
Imatinib—LCK—Innate Immune System—CD4—cervical cancer	1.48e-05	0.00015	CbGpPWpGaD
Imatinib—PDGFRA—Disease—NOTCH1—cervical cancer	1.48e-05	0.000149	CbGpPWpGaD
Imatinib—KIT—Adaptive Immune System—EGFR—cervical cancer	1.46e-05	0.000148	CbGpPWpGaD
Imatinib—PDGFRA—Immune System—CASP8—cervical cancer	1.46e-05	0.000147	CbGpPWpGaD
Imatinib—KIT—Signaling Pathways—HES1—cervical cancer	1.45e-05	0.000146	CbGpPWpGaD
Imatinib—PDGFRA—Innate Immune System—EGFR—cervical cancer	1.44e-05	0.000146	CbGpPWpGaD
Imatinib—ABL1—Developmental Biology—EGFR—cervical cancer	1.44e-05	0.000145	CbGpPWpGaD
Imatinib—LCK—Adaptive Immune System—MTOR—cervical cancer	1.43e-05	0.000144	CbGpPWpGaD
Imatinib—LCK—Adaptive Immune System—CD4—cervical cancer	1.42e-05	0.000144	CbGpPWpGaD
Imatinib—PDGFRB—Disease—FGFR3—cervical cancer	1.42e-05	0.000143	CbGpPWpGaD
Imatinib—LCK—Disease—HES1—cervical cancer	1.41e-05	0.000143	CbGpPWpGaD
Imatinib—PDGFRA—Adaptive Immune System—EGFR—cervical cancer	1.39e-05	0.00014	CbGpPWpGaD
Imatinib—CYP2C19—Metabolism—CA9—cervical cancer	1.37e-05	0.000139	CbGpPWpGaD
Imatinib—PDGFRA—Signaling Pathways—HES1—cervical cancer	1.37e-05	0.000138	CbGpPWpGaD
Imatinib—ABCB1—Metabolism—CA9—cervical cancer	1.34e-05	0.000136	CbGpPWpGaD
Imatinib—PDGFRB—Disease—NOTCH1—cervical cancer	1.33e-05	0.000134	CbGpPWpGaD
Imatinib—ABCB1—Integrated Pancreatic Cancer Pathway—EGFR—cervical cancer	1.32e-05	0.000134	CbGpPWpGaD
Imatinib—LCK—Innate Immune System—CTNNB1—cervical cancer	1.32e-05	0.000133	CbGpPWpGaD
Imatinib—PDGFRB—Immune System—CASP8—cervical cancer	1.31e-05	0.000133	CbGpPWpGaD
Imatinib—PDGFRB—Innate Immune System—EGFR—cervical cancer	1.3e-05	0.000132	CbGpPWpGaD
Imatinib—ABL1—Immune System—CASP8—cervical cancer	1.28e-05	0.000129	CbGpPWpGaD
Imatinib—ABL1—Innate Immune System—EGFR—cervical cancer	1.27e-05	0.000128	CbGpPWpGaD
Imatinib—KIT—Signaling Pathways—TERT—cervical cancer	1.27e-05	0.000128	CbGpPWpGaD
Imatinib—KIT—Immune System—MTOR—cervical cancer	1.26e-05	0.000128	CbGpPWpGaD
Imatinib—CYP2D6—Metabolism—CA9—cervical cancer	1.26e-05	0.000128	CbGpPWpGaD
Imatinib—KIT—Immune System—CD4—cervical cancer	1.26e-05	0.000128	CbGpPWpGaD
Imatinib—CYP2C9—Metabolism—CA9—cervical cancer	1.25e-05	0.000127	CbGpPWpGaD
Imatinib—PDGFRB—Adaptive Immune System—EGFR—cervical cancer	1.25e-05	0.000126	CbGpPWpGaD
Imatinib—LCK—Disease—MTHFR—cervical cancer	1.24e-05	0.000126	CbGpPWpGaD
Imatinib—LCK—Disease—TERT—cervical cancer	1.24e-05	0.000125	CbGpPWpGaD
Imatinib—PDGFRB—Signaling Pathways—HES1—cervical cancer	1.23e-05	0.000125	CbGpPWpGaD
Imatinib—LCK—Immune System—FGFR3—cervical cancer	1.23e-05	0.000124	CbGpPWpGaD
Imatinib—LCK—Signaling Pathways—NOTCH2—cervical cancer	1.21e-05	0.000122	CbGpPWpGaD
Imatinib—PDGFRA—Signaling Pathways—TERT—cervical cancer	1.2e-05	0.000121	CbGpPWpGaD
Imatinib—PDGFRA—Immune System—MTOR—cervical cancer	1.2e-05	0.000121	CbGpPWpGaD
Imatinib—PDGFRA—Immune System—CD4—cervical cancer	1.2e-05	0.000121	CbGpPWpGaD
Imatinib—ABL1—Hemostasis—TP53—cervical cancer	1.18e-05	0.00012	CbGpPWpGaD
Imatinib—KIT—Disease—MTOR—cervical cancer	1.17e-05	0.000118	CbGpPWpGaD
Imatinib—KIT—Disease—CD4—cervical cancer	1.17e-05	0.000118	CbGpPWpGaD
Imatinib—KIT—Signaling Pathways—FGFR3—cervical cancer	1.16e-05	0.000118	CbGpPWpGaD
Imatinib—LCK—Disease—FGFR3—cervical cancer	1.14e-05	0.000115	CbGpPWpGaD
Imatinib—KIT—Immune System—CTNNB1—cervical cancer	1.12e-05	0.000113	CbGpPWpGaD
Imatinib—NTRK1—Signaling Pathways—MTOR—cervical cancer	1.12e-05	0.000113	CbGpPWpGaD
Imatinib—ABCB1—Integrated Pancreatic Cancer Pathway—TP53—cervical cancer	1.11e-05	0.000112	CbGpPWpGaD
Imatinib—PDGFRA—Disease—MTOR—cervical cancer	1.11e-05	0.000112	CbGpPWpGaD
Imatinib—PDGFRA—Disease—CD4—cervical cancer	1.1e-05	0.000112	CbGpPWpGaD
Imatinib—PDGFRA—Signaling Pathways—FGFR3—cervical cancer	1.1e-05	0.000111	CbGpPWpGaD
Imatinib—KIT—Signaling Pathways—NOTCH1—cervical cancer	1.09e-05	0.00011	CbGpPWpGaD
Imatinib—PDGFRB—Signaling Pathways—TERT—cervical cancer	1.08e-05	0.000109	CbGpPWpGaD
Imatinib—PDGFRB—Immune System—MTOR—cervical cancer	1.08e-05	0.000109	CbGpPWpGaD
Imatinib—PDGFRB—Immune System—CD4—cervical cancer	1.08e-05	0.000109	CbGpPWpGaD
Imatinib—CYP1A2—Metabolism—CA9—cervical cancer	1.07e-05	0.000108	CbGpPWpGaD
Imatinib—LCK—Disease—NOTCH1—cervical cancer	1.07e-05	0.000108	CbGpPWpGaD
Imatinib—PDGFRA—Immune System—CTNNB1—cervical cancer	1.06e-05	0.000107	CbGpPWpGaD
Imatinib—LCK—Immune System—CASP8—cervical cancer	1.05e-05	0.000106	CbGpPWpGaD
Imatinib—ABL1—Immune System—MTOR—cervical cancer	1.05e-05	0.000106	CbGpPWpGaD
Imatinib—ABL1—Immune System—CD4—cervical cancer	1.05e-05	0.000106	CbGpPWpGaD
Imatinib—LCK—Innate Immune System—EGFR—cervical cancer	1.04e-05	0.000106	CbGpPWpGaD
Imatinib—KIT—Disease—CTNNB1—cervical cancer	1.04e-05	0.000105	CbGpPWpGaD
Imatinib—PDGFRA—Signaling Pathways—NOTCH1—cervical cancer	1.03e-05	0.000104	CbGpPWpGaD
Imatinib—NTRK1—Signaling Pathways—CASP3—cervical cancer	1.03e-05	0.000104	CbGpPWpGaD
Imatinib—ABCG2—Metabolism—MTHFR—cervical cancer	1.01e-05	0.000102	CbGpPWpGaD
Imatinib—LCK—Adaptive Immune System—EGFR—cervical cancer	1e-05	0.000101	CbGpPWpGaD
Imatinib—CYP3A7—Metabolism—MTHFR—cervical cancer	9.98e-06	0.000101	CbGpPWpGaD
Imatinib—SLC22A2—Metabolism—MTHFR—cervical cancer	9.97e-06	0.000101	CbGpPWpGaD
Imatinib—PDGFRB—Disease—MTOR—cervical cancer	9.96e-06	0.000101	CbGpPWpGaD
Imatinib—PDGFRB—Disease—CD4—cervical cancer	9.94e-06	0.0001	CbGpPWpGaD
Imatinib—PDGFRB—Signaling Pathways—FGFR3—cervical cancer	9.91e-06	0.0001	CbGpPWpGaD
Imatinib—NTRK1—Signaling Pathways—CTNNB1—cervical cancer	9.9e-06	0.0001	CbGpPWpGaD
Imatinib—LCK—Signaling Pathways—HES1—cervical cancer	9.89e-06	0.0001	CbGpPWpGaD
Imatinib—PDGFRA—Disease—CTNNB1—cervical cancer	9.8e-06	9.91e-05	CbGpPWpGaD
Imatinib—KIT—Immune System—STAT3—cervical cancer	9.78e-06	9.88e-05	CbGpPWpGaD
Imatinib—LCK—Hemostasis—TP53—cervical cancer	9.74e-06	9.84e-05	CbGpPWpGaD
Imatinib—PTGS1—Metabolism—MTHFR—cervical cancer	9.68e-06	9.78e-05	CbGpPWpGaD
Imatinib—PDGFRB—Immune System—CTNNB1—cervical cancer	9.56e-06	9.67e-05	CbGpPWpGaD
Imatinib—ABL1—Immune System—CTNNB1—cervical cancer	9.32e-06	9.42e-05	CbGpPWpGaD
Imatinib—PDGFRB—Signaling Pathways—NOTCH1—cervical cancer	9.31e-06	9.41e-05	CbGpPWpGaD
Imatinib—SLC22A1—Metabolism—MTHFR—cervical cancer	9.29e-06	9.39e-05	CbGpPWpGaD
Imatinib—PDGFRA—Immune System—STAT3—cervical cancer	9.25e-06	9.35e-05	CbGpPWpGaD
Imatinib—KIT—Disease—STAT3—cervical cancer	9.03e-06	9.12e-05	CbGpPWpGaD
Imatinib—KIT—Immune System—EGFR—cervical cancer	8.88e-06	8.98e-05	CbGpPWpGaD
Imatinib—PDGFRB—Disease—CTNNB1—cervical cancer	8.83e-06	8.93e-05	CbGpPWpGaD
Imatinib—LCK—Signaling Pathways—TERT—cervical cancer	8.67e-06	8.76e-05	CbGpPWpGaD
Imatinib—LCK—Immune System—MTOR—cervical cancer	8.66e-06	8.75e-05	CbGpPWpGaD
Imatinib—LCK—Immune System—CD4—cervical cancer	8.64e-06	8.74e-05	CbGpPWpGaD
Imatinib—NTRK1—Signaling Pathways—STAT3—cervical cancer	8.63e-06	8.72e-05	CbGpPWpGaD
Imatinib—PDGFRA—Disease—STAT3—cervical cancer	8.54e-06	8.64e-05	CbGpPWpGaD
Imatinib—PDGFRA—Immune System—EGFR—cervical cancer	8.41e-06	8.5e-05	CbGpPWpGaD
Imatinib—PDGFRB—Immune System—STAT3—cervical cancer	8.34e-06	8.43e-05	CbGpPWpGaD
Imatinib—CYP3A4—Metabolism—CA9—cervical cancer	8.27e-06	8.36e-05	CbGpPWpGaD
Imatinib—KIT—Disease—EGFR—cervical cancer	8.2e-06	8.29e-05	CbGpPWpGaD
Imatinib—KIT—Signaling Pathways—MTOR—cervical cancer	8.18e-06	8.27e-05	CbGpPWpGaD
Imatinib—ABL1—Immune System—STAT3—cervical cancer	8.12e-06	8.21e-05	CbGpPWpGaD
Imatinib—LCK—Disease—MTOR—cervical cancer	7.99e-06	8.08e-05	CbGpPWpGaD
Imatinib—LCK—Disease—CD4—cervical cancer	7.98e-06	8.07e-05	CbGpPWpGaD
Imatinib—LCK—Signaling Pathways—FGFR3—cervical cancer	7.96e-06	8.04e-05	CbGpPWpGaD
Imatinib—NTRK1—Signaling Pathways—EGFR—cervical cancer	7.84e-06	7.93e-05	CbGpPWpGaD
Imatinib—PDGFRA—Disease—EGFR—cervical cancer	7.76e-06	7.85e-05	CbGpPWpGaD
Imatinib—PDGFRA—Signaling Pathways—MTOR—cervical cancer	7.74e-06	7.83e-05	CbGpPWpGaD
Imatinib—PDGFRB—Disease—STAT3—cervical cancer	7.7e-06	7.78e-05	CbGpPWpGaD
Imatinib—LCK—Immune System—CTNNB1—cervical cancer	7.67e-06	7.76e-05	CbGpPWpGaD
Imatinib—PDGFRB—Immune System—EGFR—cervical cancer	7.58e-06	7.66e-05	CbGpPWpGaD
Imatinib—KIT—Signaling Pathways—CASP3—cervical cancer	7.52e-06	7.6e-05	CbGpPWpGaD
Imatinib—LCK—Signaling Pathways—NOTCH1—cervical cancer	7.47e-06	7.55e-05	CbGpPWpGaD
Imatinib—ABL1—Immune System—EGFR—cervical cancer	7.38e-06	7.46e-05	CbGpPWpGaD
Imatinib—KIT—Signaling Pathways—CTNNB1—cervical cancer	7.25e-06	7.33e-05	CbGpPWpGaD
Imatinib—CYP3A5—Metabolism—MTHFR—cervical cancer	7.22e-06	7.3e-05	CbGpPWpGaD
Imatinib—PDGFRA—Signaling Pathways—CASP3—cervical cancer	7.12e-06	7.2e-05	CbGpPWpGaD
Imatinib—LCK—Disease—CTNNB1—cervical cancer	7.09e-06	7.16e-05	CbGpPWpGaD
Imatinib—PDGFRB—Disease—EGFR—cervical cancer	7e-06	7.07e-05	CbGpPWpGaD
Imatinib—PDGFRB—Signaling Pathways—MTOR—cervical cancer	6.97e-06	7.05e-05	CbGpPWpGaD
Imatinib—PDGFRA—Signaling Pathways—CTNNB1—cervical cancer	6.86e-06	6.94e-05	CbGpPWpGaD
Imatinib—LCK—Immune System—STAT3—cervical cancer	6.69e-06	6.76e-05	CbGpPWpGaD
Imatinib—NTRK1—Signaling Pathways—TP53—cervical cancer	6.58e-06	6.65e-05	CbGpPWpGaD
Imatinib—PDGFRB—Signaling Pathways—CASP3—cervical cancer	6.41e-06	6.49e-05	CbGpPWpGaD
Imatinib—KIT—Signaling Pathways—STAT3—cervical cancer	6.32e-06	6.39e-05	CbGpPWpGaD
Imatinib—ALB—Metabolism—MTHFR—cervical cancer	6.21e-06	6.28e-05	CbGpPWpGaD
Imatinib—PDGFRB—Signaling Pathways—CTNNB1—cervical cancer	6.18e-06	6.25e-05	CbGpPWpGaD
Imatinib—LCK—Disease—STAT3—cervical cancer	6.18e-06	6.24e-05	CbGpPWpGaD
Imatinib—LCK—Immune System—EGFR—cervical cancer	6.08e-06	6.15e-05	CbGpPWpGaD
Imatinib—PDGFRA—Signaling Pathways—STAT3—cervical cancer	5.98e-06	6.05e-05	CbGpPWpGaD
Imatinib—ALB—Hemostasis—TP53—cervical cancer	5.82e-06	5.88e-05	CbGpPWpGaD
Imatinib—KIT—Signaling Pathways—EGFR—cervical cancer	5.74e-06	5.81e-05	CbGpPWpGaD
Imatinib—LCK—Disease—EGFR—cervical cancer	5.61e-06	5.68e-05	CbGpPWpGaD
Imatinib—LCK—Signaling Pathways—MTOR—cervical cancer	5.6e-06	5.66e-05	CbGpPWpGaD
Imatinib—CYP2C19—Metabolism—MTHFR—cervical cancer	5.58e-06	5.64e-05	CbGpPWpGaD
Imatinib—ABCB1—Metabolism—MTHFR—cervical cancer	5.45e-06	5.51e-05	CbGpPWpGaD
Imatinib—PDGFRA—Signaling Pathways—EGFR—cervical cancer	5.44e-06	5.5e-05	CbGpPWpGaD
Imatinib—PDGFRB—Signaling Pathways—STAT3—cervical cancer	5.39e-06	5.45e-05	CbGpPWpGaD
Imatinib—LCK—Signaling Pathways—CASP3—cervical cancer	5.15e-06	5.2e-05	CbGpPWpGaD
Imatinib—CYP2D6—Metabolism—MTHFR—cervical cancer	5.13e-06	5.19e-05	CbGpPWpGaD
Imatinib—CYP2C9—Metabolism—MTHFR—cervical cancer	5.09e-06	5.14e-05	CbGpPWpGaD
Imatinib—LCK—Signaling Pathways—CTNNB1—cervical cancer	4.96e-06	5.02e-05	CbGpPWpGaD
Imatinib—PDGFRB—Signaling Pathways—EGFR—cervical cancer	4.9e-06	4.95e-05	CbGpPWpGaD
Imatinib—KIT—Signaling Pathways—TP53—cervical cancer	4.82e-06	4.88e-05	CbGpPWpGaD
Imatinib—PDGFRA—Signaling Pathways—TP53—cervical cancer	4.57e-06	4.62e-05	CbGpPWpGaD
Imatinib—CYP1A2—Metabolism—MTHFR—cervical cancer	4.35e-06	4.39e-05	CbGpPWpGaD
Imatinib—LCK—Signaling Pathways—STAT3—cervical cancer	4.33e-06	4.37e-05	CbGpPWpGaD
Imatinib—PDGFRB—Signaling Pathways—TP53—cervical cancer	4.11e-06	4.16e-05	CbGpPWpGaD
Imatinib—LCK—Signaling Pathways—EGFR—cervical cancer	3.93e-06	3.97e-05	CbGpPWpGaD
Imatinib—CYP3A4—Metabolism—MTHFR—cervical cancer	3.35e-06	3.39e-05	CbGpPWpGaD
Imatinib—LCK—Signaling Pathways—TP53—cervical cancer	3.3e-06	3.34e-05	CbGpPWpGaD
